Radiotherapy plus zoledronate is superior to radiotherapy alone in treating patients with bone metastases from renal cell carcinoma (RCC), new findings suggest. Toshiki Kijima, MD, and colleagues at ...

LOUISVILLE, Ky. -- Patients with bone-predominant metastatic renal cell carcinoma (RCC) appeared to have better outcomes when they started treatment with a targeted drug, results of a small ...

CHICAGO—Bone metastases (BM) predict shorter progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents, ...

Non-clear cell renal cell carcinoma in the immune checkpoint era: A retrospective study on survival and treatment approaches. Multivariable Cox regression models demonstrating variables associated ...

Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease–associated tumors: Results of LITESPARK-015 study. This is an ASCO Meeting Abstract from the 2025 ASCO ...

A new nano-sized drug carrier that finds bone tumors and releases treatment exactly where it's needed is here to improve the precision and comfort of cancer therapy. Designed by a team of researchers ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

This image shows an 'erythroblastic island,' a tiny factory where new red blood cells are made. The pink cells are developing red blood cells, which gather around a central blue-stained macrophage ...

Zoledronic acid has several advantages over other bisphosphonates. In addition to having broader clinical utility, zoledronic acid can safely be infused over 15 minutes rather than the 2 hours ...